Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Total Current Liabilities (2021 - 2025)

Senti Biosciences (SNTI) has 5 years of Total Current Liabilities data on record, last reported at $12.0 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities rose 32.69% year-over-year to $12.0 million; the TTM value through Sep 2025 reached $12.0 million, up 32.69%, while the annual FY2024 figure was $13.1 million, 3.74% up from the prior year.
  • Total Current Liabilities reached $12.0 million in Q3 2025 per SNTI's latest filing, up from $10.0 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $18.1 million in Q4 2022 and bottomed at $61025.0 in Q2 2021.
  • Average Total Current Liabilities over 5 years is $10.6 million, with a median of $10.6 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 29065.1% in 2022, then plummeted 41.42% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $14.5 million in 2021, then increased by 24.14% to $18.1 million in 2022, then fell by 29.81% to $12.7 million in 2023, then increased by 3.74% to $13.1 million in 2024, then fell by 8.51% to $12.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $12.0 million in Q3 2025, $10.0 million in Q2 2025, and $10.7 million in Q1 2025.